Giordano Botta: VA and Allelica Partner on Clinical Study of PRS and PGx in Cardiovascular Prevention
Giordano Botta, CEO and Co-Founder of Allelica, shared a post on LinkedIn:
“We are proud to partner with the U.S. Department of Veterans Affairs, the largest integrated healthcare system in the United States, on a randomized clinical trial evaluating the impact of polygenic risk score (PRS) and pharmacogenomics (PGx) in routine care.
This comes at a pivotal moment, as the new 2026 ACC/AHA guidelines now include PRS as a risk enhancing factor.
The study will compare standard care with a genomic guided approach.
Patients in the intervention arm will receive the Allelica multi-ancestry PRS for coronary artery disease together with PGx testing for statin response, including SLCO1B1.
The objective is to assess whether integrating genetic risk and drug response can improve statin prescription, adherence, and ultimately cardiovascular outcomes.
We look forward to supporting this clinical trial, designed to generate prospective evidence on the clinical utility of integrating PRS and PGx into cardiovascular prevention, with the potential to inform implementation at scale across large healthcare systems.”
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 12:49Ahmed Hawash: The Hawash Method for Managing Extreme ICU Complexity
-
Aug 14, 2026, 12:42Why Unfractionated Heparin Still Matters in Modern Anticoagulation – Thrombosis Canada
-
Aug 14, 2026, 11:40Liz Devlin: When HHT Affects More Than What We Can See
-
Aug 14, 2026, 11:29Archil Jaliashvili: Can Italy Reduce Its Dependence on Imported Plasma
-
Aug 14, 2026, 11:21Osama Alabdi: Never Ignore a Weak Reaction in the Blood Bank
-
Aug 14, 2026, 11:14Yohan Santin: How Lysosomal Dysfunction Drives Cardiac Aging
-
Aug 14, 2026, 11:06Nicolas Schommer: When Neutrophils Turn Metabolic Stress Into Organ Injury
-
Aug 14, 2026, 10:49Pablo Corral: Can One Infusion Lower LDL for Years
-
Aug 14, 2026, 08:17Maha Othman: Celebrating Research and Collaboration at the Sinclair Cancer Research Institute 2026 Annual Retreat